Gilead Sciences, Inc.
GILD
$138.92
$0.560.41%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 30.46B | 29.73B | 29.44B | 29.09B | 28.86B |
| Total Other Revenue | 1.00M | 2.00M | 2.00M | 1.00M | 1.00M |
| Total Revenue | 30.46B | 29.74B | 29.44B | 29.09B | 28.86B |
| Cost of Revenue | 6.21B | 6.14B | 6.23B | 6.19B | 6.20B |
| Gross Profit | 24.24B | 23.60B | 23.21B | 22.90B | 22.67B |
| SG&A Expenses | 6.46B | 5.91B | 5.71B | 5.79B | 5.85B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.62B | 17.75B | 17.63B | 17.72B | 17.83B |
| Operating Income | 11.84B | 11.98B | 11.82B | 11.37B | 11.03B |
| Income Before Tax | -1.96B | 10.73B | 9.80B | 9.89B | 7.20B |
| Income Tax Expenses | 1.29B | 1.51B | 1.29B | 1.78B | 890.00M |
| Earnings from Continuing Operations | -3.24K | 9.22K | 8.51K | 8.11K | 6.31K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.24B | 9.22B | 8.51B | 8.11B | 6.31B |
| EBIT | 11.84B | 11.98B | 11.82B | 11.37B | 11.03B |
| EBITDA | 14.60B | 14.74B | 14.58B | 14.13B | 13.80B |
| EPS Basic | -2.60 | 7.41 | 6.84 | 6.51 | 5.06 |
| Normalized Basic EPS | 5.61 | 5.69 | 5.60 | 5.37 | 5.18 |
| EPS Diluted | -2.67 | 7.34 | 6.77 | 6.44 | 5.01 |
| Normalized Diluted EPS | 5.57 | 5.64 | 5.55 | 5.32 | 5.14 |
| Average Basic Shares Outstanding | 4.97B | 4.97B | 4.98B | 4.98B | 4.99B |
| Average Diluted Shares Outstanding | 5.00B | 5.02B | 5.02B | 5.03B | 5.03B |
| Dividend Per Share | 3.22 | 3.19 | 3.16 | 3.14 | 3.12 |
| Payout Ratio | -125.56% | 43.76% | 47.04% | 49.10% | 62.75% |